Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Curve vs PreventiveMD

Curve
Graded #289

Lower grade

vs+14.399999999999991
PreventiveMD
Graded #54

Higher grade

The verdict

PreventiveMD takes it — 76.1/100 to 61.7/100.

PreventiveMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PreventiveMD is a physician-guided telehealth platform for GLP-1 weight loss and peptide therapy, offering compounded semaglutide from $83/mo all-in and compounded tirzepatide from $97/mo all-in, plus brand…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePreventiveMD +27
57
84
Dose & formulationPreventiveMD +18
64
82
Clinical oversightPreventiveMD +14
68
82
Labs & monitoringPreventiveMD +1
52
53
FulfillmentCurve +14
97
83
Contract termsPreventiveMD +35
20
55
Curve · left barPreventiveMD · right bar

The numbers

MetricCurvePreventiveMD
WeighScore61.7/10076.1/100
GradeCC
Scorecard rank#289#54
Semaglutide$175/mo (compounded)$83/mo (starting dose, compounded)
Tirzepatide$225/mo (compounded)$97/mo (starting dose, compounded)
CoverageAll 50 states36 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Curve

Graded #289 · C

Strengths

  • Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
  • LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
  • Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
  • Available in all 50 states with same-day provider review; no insurance needed and HSA/FSA accepted.

Where it loses points

  • Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
  • The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
  • Both product pages currently display an out-of-stock status, so availability may be inconsistent.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
PreventiveMD

Graded #54 · C

Strengths

  • Compounded semaglutide from $83/mo and tirzepatide from $97/mo, billed as one all-in monthly price
  • Brand Wegovy, Zepbound, and Foundayo (oral GLP-1) available on the same platform
  • US-licensed provider reviews requests within 24 hours — no video visit required
  • You aren't charged until a provider approves; checkout places an authorization hold only
  • LegitScript-certified; works exclusively with state-licensed US 503A compounding pharmacies

Where it loses points

  • Individual compounding pharmacy partners are not publicly named
  • Not available in 14 states + DC, including New York, New Jersey, Virginia, and Wisconsin
  • Brand Wegovy, Zepbound, and Foundayo require a $49/mo membership fee on top of medication cost
  • 'As low as' pricing — actual monthly cost can be higher depending on your plan
  • Orders become non-refundable once provider review or pharmacy fulfillment begins

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard